New eczema gel shows promise in early trial
NCT ID NCT04992546
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new topical gel called PRN473 (SAR444727) in 39 adults with mild to moderate atopic dermatitis (eczema). Each participant had two similar patches of eczema treated: one with the study gel and one with a placebo gel, without knowing which was which. The main goals were to check safety and how the body processes the drug. The study lasted about 13 weeks and is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRN473 (SAR444727) topical gel
What this could lead to
If successful, this could lead to a new topical treatment option for mild to moderate eczema that is applied directly to the skin.
What could go wrong
This was a small, early-phase study (Phase 2a) with only 39 participants. The results may not apply to everyone, and the treatment may not prove effective in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Allergy & Asthma Medical Group-Site Number:8400008
Los Angeles, California, 90025, United States
-
Center for Clinical Studies, LTD. LLP-Site Number:8400014
Houston, Texas, 77004, United States
-
Clinical Research Trials of Florida, Inc-Site Number:8400013
Tampa, Florida, 33607, United States
-
Collaborative Neuroscience Research-Site Number:8400004
Long Beach, California, 90806, United States
-
Florida International Research Center-Site Number:8400017
Miami, Florida, 33173, United States
-
Investigational Site Number :1240002
Québec, G1G 3Y8, Canada
-
Investigational Site Number :1240007
London, Ontario, N6H 5L5, Canada
-
Investigational Site Number :1240008
Hamilton, Ontario, L8L 3C3, Canada
-
J&S Studies-Site Number:8400015
Bryan, Texas, 77802, United States
-
Lenus Research & Medical Group-Site Number:8400006
Sweetwater, Florida, 33172, United States
-
Progressive Clinical Research-Site Number:8400002
San Antonio, Texas, 78213, United States
-
Remington Davis Inc-Site Number:8400012
Columbus, Ohio, 43215, United States